152 related articles for article (PubMed ID: 34046604)
1. Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
Fernández de Luco J; Recio-Balsells AI; Ghiano DG; Bortolotti A; Belardinelli JM; Liu N; Hoffmann P; Lherbet C; Tonge PJ; Tekwani B; Morbidoni HR; Labadie GR
RSC Med Chem; 2021 Jan; 12(1):120-128. PubMed ID: 34046604
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
3. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.
Pflégr V; Horváth L; Stolaříková J; Pál A; Korduláková J; Bősze S; Vinšová J; Krátký M
Eur J Med Chem; 2021 Nov; 223():113668. PubMed ID: 34198149
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Highly Active Antimycobacterial Mutual Esters of 2-(2-Isonicotinoylhydrazineylidene)propanoic Acid.
Pflégr V; Maixnerová J; Stolaříková J; Pál A; Korduláková J; Trejtnar F; Vinšová J; Krátký M
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959704
[TBL] [Abstract][Full Text] [Related]
6. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.
Betts JC; McLaren A; Lennon MG; Kelly FM; Lukey PT; Blakemore SJ; Duncan K
Antimicrob Agents Chemother; 2003 Sep; 47(9):2903-13. PubMed ID: 12936993
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
[TBL] [Abstract][Full Text] [Related]
8. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
Kuo MR; Morbidoni HR; Alland D; Sneddon SF; Gourlie BB; Staveski MM; Leonard M; Gregory JS; Janjigian AD; Yee C; Musser JM; Kreiswirth B; Iwamoto H; Perozzo R; Jacobs WR; Sacchettini JC; Fidock DA
J Biol Chem; 2003 Jun; 278(23):20851-9. PubMed ID: 12606558
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
10. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
11. Triclosan and its derivatives as antimycobacterial active agents.
Vosátka R; Krátký M; Vinšová J
Eur J Pharm Sci; 2018 Mar; 114():318-331. PubMed ID: 29277667
[TBL] [Abstract][Full Text] [Related]
12. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
13. New one-pot synthesis of anti-tuberculosis compounds inspired on isoniazid.
Ghiano DG; Recio-Balsells A; Bortolotti A; Defelipe LA; Turjanski A; Morbidoni HR; Labadie GR
Eur J Med Chem; 2020 Dec; 208():112699. PubMed ID: 32927391
[TBL] [Abstract][Full Text] [Related]
14. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents.
Phatak PS; Bakale RD; Kulkarni RS; Dhumal ST; Dixit PP; Krishna VS; Sriram D; Khedkar VM; Haval KP
Bioorg Med Chem Lett; 2020 Nov; 30(22):127579. PubMed ID: 32987135
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
[TBL] [Abstract][Full Text] [Related]
18. New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.
Nayak N; Ramprasad J; Dalimba U
Bioorg Med Chem Lett; 2015 Dec; 25(23):5540-5. PubMed ID: 26520663
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitubercular activity of heterocycle substituted diphenyl ether derivatives.
Kini SG; Bhat A; Pan Z; Dayan FE
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):730-6. PubMed ID: 20443682
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
